Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MAXIDEX
- Elimination of Minimal Residual Disease After Transplant
- Topical Insulin Versus Autologous Serum After Corneal Surgeries
- Marizomib Central Nervous System (CNS)
- Venetoclax Plus Inotuzumab for B-ALL
- COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
- Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime
- Use of Prophylactic Lubricating Drops After Cataract Surgery
- Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
- Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
- A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
- Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
- Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
- A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Systane Ultra Versus Maxidex Versus Saline
- A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclopho
- SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
- Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
- AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation
- Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
- To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
- Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
- Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
- R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- ABT-751 With Chemotherapy for Relapsed Pediatric ALL
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
- Prevention of Docetaxel Induced Dacryostenosis
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Clinical trials list
click for details